Cellectar Biosciences (CLRB) to Release Earnings on Monday

Cellectar Biosciences (NASDAQ:CLRB) is scheduled to release its earnings data before the market opens on Monday, November 18th. Analysts expect Cellectar Biosciences to post earnings of ($0.34) per share for the quarter.

Cellectar Biosciences (NASDAQ:CLRB) last announced its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported ($0.51) EPS for the quarter. On average, analysts expect Cellectar Biosciences to post $-2 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Cellectar Biosciences Stock Performance

Shares of CLRB stock opened at $2.12 on Tuesday. Cellectar Biosciences has a fifty-two week low of $1.82 and a fifty-two week high of $4.45. The stock’s fifty day moving average price is $2.08 and its two-hundred day moving average price is $2.46. The company has a market cap of $86.01 million, a PE ratio of -0.84 and a beta of 1.00.

Analysts Set New Price Targets

Several research firms recently weighed in on CLRB. StockNews.com raised Cellectar Biosciences to a “sell” rating in a research note on Thursday, September 26th. Oppenheimer restated an “outperform” rating and issued a $14.00 price target on shares of Cellectar Biosciences in a research note on Friday, October 11th.

About Cellectar Biosciences

Cellectar Biosciences, Inc, a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer.